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Abstract: Type 1 diabetes (T1DM) is associated with increased cardiovascular disease (CVD) and
reduced life expectancy. We thus hypothesized that anti-angiogenic miRs are increased in T1DM,
and the cardioprotective effect of metformin is mediated via reducing those miRs. In an open
label, case-controlled study, 23 T1DM patients without CVD were treated with metformin for eight
weeks (TG), matched with nine T1DM patients on standard treatment (SG) and 23 controls (CG).
Plasma miR-222, miR-195, miR-21a and miR-126 were assayed by real-time RT-qPCR. The results were
correlated with: endothelial function (RHI), circulating endothelial progenitor cells (cEPCs) (vascular
repair marker, CD45dimCD34+VEGFR2+ cells) and circulating endothelial cells (cECs) (vascular
injury marker, CD45dimCD34+CD133-CD144+ cells). miR-222, miR-195 and miR-21a were higher
in T1DM than CG; p = 0.009, p < 0.0001, p = 0.0001, respectively. There was an inverse correlation
between logmiR-222 and logRHI (p < 0.05) and a direct correlation between logmiR-222 and logCD34+
(p < 0.05) in TG. Metformin reduced miR-222, miR-195 and miR-21a levels in TG; p = 0.007, p = 0.002
p = 0.0012, respectively. miRs remained unchanged in SG. miR-126 was similar in all groups. There
was a positive association between changes in logmiR-222 and logcECs after metformin in TG
(p < 0.05). Anti-angiogenic miRs are increased in T1DM. Metformin has cardioprotective effects
through downregulating miR-222, miR-195 and miR-21a, beyond improving glycemic control.
Keywords: T1DM; metformin; anti-angiogenic; miRs
1. Introduction
Cardiovascular disease (CVD) remains the number one cause of death worldwide according to a
2016 World Health Organization report. The outcome of CVD management is affected by diabetes
mellitus (DM), which results in a two- to four-fold increased risk of CVD [1]. The results of CVD
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interventions such as percutaneous coronary intervention (PCI) and coronary artery bypass graft
in patients with DM are much worse than in non-diabetic individuals [2]. More recently, data have
become available for type 1 DM (T1DM), not previously considered to be a high CVD risk, showing an
increased risk for CVD, coronary heart disease (CHD), stroke and consequent all-cause mortality [3].
Overall, the largest percentage of the estimated loss in life expectancy was related to ischemic heart
disease (36% in men, 31% in women) [3]. Thus, in order to improve the outcome of CVD patients and
with T1DM in particular, it is paramount to understand the mechanisms involved in diabetes-associated
CVD complications.
Metformin is the first hypoglycemic drug to display cardioprotective properties in type 2 diabetes
as shown in a long-term randomized clinical trial [4]. A recent study in T1DM has shown that
although progression of mean carotid intima media thickness (cIMT) was not significantly reduced
with metformin, the maximal cIMT (a pre-specified tertiary outcome) was significantly reduced [5].
Furthermore, when metformin was used in patients with metabolic syndrome, the duration of post-PCI
myocardial injury was decreased by seven days [6]. The pre-treatment of diabetic patients with
metformin was found to be associated with reduced myocardial infarction (MI) size compared to
non-metformin-treated patients [7]. Additionally, studies in diabetic animal models have suggested
that metformin, in physiological doses, improves coronary blood flow following MI [8] and limits
infarct size in type 2 diabetic rats [9]. It has also been shown that the vasculo-protective effects
of metformin are independent of its anti-hyperglycemic and lipid lowering effects [10]. In animal
models, metformin has prevented the development of pulmonary hypertension [10]. Metformin
has also improved heart failure and survival in animals via activation of the AMPK pathway and its
downstream mediators, endothelial nitric oxide synthase (eNOS) and peroxisome proliferator-activated
receptor-gamma coactivator 1 (PGC-1). Furthermore, metformin-mediated cardioprotection was
achieved independently of its effect on glucose levels [11].
Our recent work has shown that metformin, in vitro, improved angiogenesis by augmenting the
expression of vascular endothelial growth factor A (VEGFA) and reducing the angiogenic inhibitors
in CD34+ cells [12]. Furthermore, metformin upregulates VEGF receptors (VEGFR1/R2), fatty acid
binding protein 4, ERK/mitogen-activated protein kinase signaling, chemokine ligand 8, lymphocyte
antigen 96, Rho kinase 1, matrix metalloproteinase 16 (MMP16) and tissue factor inhibitor-2 in human
umbilical endothelial cells exposed to hyperglycemia-hypoxia [13]. In our clinical trial in T1DM (MERIT
Study), metformin improved levels of circulating endothelial progenitor cells (cEPCs), vascular repair
markers (CD45dimCD34+VEGFR2+) and circulating endothelial cells (cECs), vascular injury markers
(CD45dimCD34+CD144+CD133-), whilst being unchanged in diabetic control [14]. Other pleiotropic
effects of metformin were documented in non-diabetic ApoE−/− mice and showed amelioration of
atherosclerosis and vascular senescence [15]. The cardioprotective mechanism behind metformin
action is poorly understood in clinical practice. Therefore, if we understand its mode of action, this
could facilitate the development of novel therapies for CVD in diabetes.
MicroRNAs (miRs) are a class of small, single-stranded, non-coding RNAs (~19–22 nucleotides)
that function mainly in gene silencing by either repressing the translational process of target messenger
RNAs (mRNAs) and/or enhancing target mRNAs’ degradation. Cell-derived miRs circulating in
various body fluids are resistant to RNase activity and thus are suitable for assessing cell-to-cell
communication and the monitoring of therapeutic interventions [16]. Numerous miRs have been
identified as significant diagnostic or prognostic markers for CVD [17]. Multiple miRs, miR-1, miR-208a,
miR-208b, miR-133a, miR-133b and miR-499, have been shown to be elevated in the plasma of patients
with acute ischemic injury [18–21]. In addition to their diagnostic value, miRs have been identified
to have prognostic value in patients with myocardial infarction, levels of miR-208b and miR-133a
being correlated with increased mortality [22]. Elevated miR-1 levels are associated with a future risk
of heart failure in patients with acute myocardial infarction [23]. miRs have been also identified as
markers of the size of the myocardial injury [24]. However, our understanding of them is limited,
and further work needs to be carried out to understand the mechanisms by which miRs play a role
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in CVD. We decided to explore the effect of metformin on four miRs, miR-222, miR-195, miR-21a
and miR-126 based on their role as angiogenic and anti-angiogenic factors. These miRs appear to
be deregulated in the plasma of diabetic individuals [25,26]. We therefore hypothesized that plasma
levels of the anti-angiogenic miRs, miR-222, miR-195 and miR-21a are raised in T1DM, whilst the level
of the angiogenic miR-126 is decreased, and the cardioprotective effect of metformin is mediated by
modulating the levels of circulating miRs involved in angiogenesis; this is achieved beyond improving
glycemic control.
2. Results
Patients’ characteristics have been discussed previously [14] and are provided in Table 1. Briefly,
the treatment group (TG), standard group (SG) and healthy control group (CG) were well-matched
for age, gender and blood pressure. Except for BMI, TG and SG were well-matched for duration of
diabetes, HbA1c, baseline insulin dose, lipid profile and creatinine. In order to maintain unchanged
diabetic control, insulin dose including insulin pump dose in the TG was significantly reduced
(median 44 units, range 10.7–161, versus median 39 units, range 9.3–148, p = 0.0002). HbA1c remained
unchanged between TG Visit 1 and TG Visit 2 (Table 1). Metabolic parameters (HbA1c, BMI, total
cholesterol, triglyceride and blood pressure) were similar in both the TG and SG.
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Table 1. Subjects’ clinical and metabolic characteristics.
Characteristics
TG (n = 23) p-Value
TG V1 vs. V2
HC
(n = 23)
p-Value
HC vs. TG V1
SG (n = 9) p-Value
SG V1 vs. V2
p-Value
SG V1 vs. TG V1TG V1 TG V2 SG V1 SG V2
Age year 46 ± 13 − − 46 ± 12.6 1 47.4 ± 13.6 − − 0.8
Sex M/F n 11/12 − − 11/12 − 5/4 − − −
DOD years 23 ± 13.6 − − − − 23.7 ± 14.1 − − 0.9
BMI kg/m2 28.7 (24–32) 29 (23–32) >0.05 26.2 ± 4.7 0.1 23.8 (22–27) 23.7 (21.3–27.1) 0.3 <0.05
Systolic BP mmHg 125 ± 10.8 121 ± 14 0.2 119.4 ± 9 0.2 132.8 ± 6.2 130.8 ± 12.1 0.7 0.05
Diastolic BP mmHg 76.2 ± 9.2 74 ± 7 0.1 75.7 ± 9 0.9 77 ± 8.2 72.9 ± 3.6 0.4 0.8
HbA1c mmol/mol 56.9 ± 10.5 55.9 ± 8.5 0.5 34.8 ± 2.9 <0.0001 58.6 ± 7.4 59 ± 9 0.7 0.6
HbA1c % 7.3 ± 0.9 7.3 ± 0.8 0.6 5.3 ± 0.3 <0.0001 7.5 ± 0.70 7.5 ± 0.8 0.6 0.6
Insulin dose units 44 (20–69) 39 (18–66) <0.001 − − 52.3 ± 11 52.9 ± 11 0.5 0.4
Smoking Y/E/N 4/2/17 − − 0/0/23 2/1/6 − − −
Total cholesterol mmol/L 4.5 ± 0.8 4.4 ± 1 0.2 4.96 ± 0.8 0.1 4.8 ± 1.3 4.9 ± 1.4 0.8 0.7
Triglyceride mmol/L 0.9 ± 0.4 0.9 ± 0.4 0.9 1.5 ± 0.9 0.008 0.7 ± 0.32 0.7 ± 0.3 0.6 0.2
HDL-cholesterol mmol/L 1.8 ± 0.5 1.6 ± 0.4 <0.05 1.6 ± 0.4 0.1 1.9 ± 0.6 2.1 ± 0.6 0.4 0.5
Creatinine µmol/L 73 (68–94) 70 (63–77) 0.01 78 (70–87) 0.3 75 (65–87) 77 (62.8–83.5) 0.7 0.7
WCC cells/mL 6.4 ± 2.4 6.3 ± 2 0.7 6.3 ± 1.6 0.9 5.8 ± 1.5 5.6 ± 1.7 0.9 0.5
Values are given as mean ± SD or * median (interquartile range (IQ). kg, kilogram; BMI, body mass index; BP, blood pressure; M, male; F, female; DOD, duration of diabetes; Y, yes; E,
ex-smoker; N, no. TG V1, pre-treatment; TG V2, post-treatment; SG V1, pre-observation; SG V2, post-observation; V1, visit 1; V2, visit 2; WCC, white cell count. * HbA1c TG V2 vs. SG V2
p = 0.6.
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2.1. miRs
At baseline, plasma miR-222, miR-195 and miR-21a levels were significantly higher in the TG
V1 when compared with the CG p = 0.009, p < 0.0001, p = 0.0001 (Figure 1a–c), respectively. Plasma
miR-195 and miR-21a levels were significantly higher in the SG V1 compared with the CG (p = 0.0012
and p = 0.02, respectively, Figure 1b,c), whilst the expression of miR-222 was not significantly different
between the SG V1 and CG (Figure 1a). At baseline, plasma miR-222 and miR-21a levels were similar
in TG V1 compared with SG V1 (pre-observation, Figure 1a,c). Whereas, plasma miR-195 level was
significantly higher in TG V1 when compared with SG V1 (p = 0.03, Figure 1b), there was a significant
difference in miR-195 and miR-21a plasma levels in SG V1 compared with CG (p = 0.0012 and p = 0.02,
respectively, Figure 1b,c). There was no significant difference in miR-222 expression in the SG V1 and
CG (Figure 1a).
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Figure 1. (a–c) A comparison of miR-222, miR-195 and miR-21a levels in plasma for all groups.
At baseline (TG V1), miR-222, miR-195 and miR-21a levels were significantly upregulated in the TG
compared to healthy controls (CG). The levels of miR-222, miR-195 and miR-21a were all significantly
reduced in the TG after metformin therapy (TG V2). The results are presented as the mean ± SEM.
Within the TG and SG, the comparison was analyzed using the paired Student t-test. An unpaired
Student t-test was used to compare the healthy controls and patients’ groups. Treatment group
pre-metformin (TG V1), treatment group post-metformin (TG V2), standard group pre-observation
(SG V1) and standard group post-observation (SG V2). * p < 0.05, ** p < 0.01, *** p < 0.001.
2.2. The Correlation between miR-222 and Indices of Vascular Health
At baseline, there was a significant inverse correlation between logmiR-222 and the flow-mediated
dilatation reactive hyperemia index (RHI, clinical measure of endothelial function) log(RHI), r = −0.52;
p < 0.05 in T1DM (Figure 2). Additionally, a direct positive correlation between logmiR-222 and
logCD34+ (r = 0.42; p < 0.05) was observed in TG at baseline (Figure 3).
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Figure 3. The significant correlation betwe n levels of circulating miR-222 (logmiR222) and CD34+ cells
(log CD34+) at bas line. CD34+ were analyzed by flow cytometry. The relationship was demonstrated
by Pearson correlation.
2.3. Anti-Angiogenic miRs Reduced by Metformin
2.3.1. miR-222
Eight weeks of metformin treatment significantly reduced the plasma levels of miR-222 in the
TG, p = 0.007 (Figure 1a). After metformin treatment, plasma miR-222 levels were normalized in the
TG in comparison to the GC. In the SG, plasma miR-222 remained unchanged after eight weeks of
observation. There was also a direct positive correlation between changes in logmiR-222 and changes
in logcEC, r = 0.42; p < 0.05, in the TG (Figure 4).
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2.3.2. miR-195
After eight weeks of metformin treatment, plasma miR-195 levels were significantly reduced in
the TG, p = 0.002 (Figure 1b), whereas they remained unchanged aft r ight weeks of observation. No
association was identified betwe n changes in RHI, CD34+, cECs and miR-195 (p > 0.05).
2.3.3. miR-21a
Eight weeks of metformin treatment significantly reduced plasma miR-21a levels in the TG
p = 0.0012 (Figure 1c), whilst they remained unchanged after eight weeks of observation. No association
was identified between changes in RHI, CD34+, cECs and miR-21a (p > 0.05).
2.3.4. miR-126
Plasma miR-126 levels were similar in all the groups studied. In the TG, eight weeks of metformin
treatment did not alter plasma miR-126 levels. Additionally, in the SG plasma, miR-126 remained
unchanged after eight weeks of observation (Figure 5).
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Figure 5. A comparison of the plasma levels of miR-126 (per mL) in all groups. The results are presented
as the mean ± SEM. Treatment group pre-metformin (TG V1), treatment group post-metformin (TG
V2), standard group pre-observation (SG V1) and standard group post-obse vation (SG V2).
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2.4. Anti-Angiogenic miRs Pathway Identification
We predicted the biological pathways that would be affected by a significant decrease in the levels
of the anti-angiogenic miRs miR-222 we studied, miR-195 and miR-21a (Figure 6), using the DIANA
miRPATH (Version 3) software [27]. Analysis of the pathways demonstrated that the reduction in
plasma levels of these miRs might affect angiogenesis, cellular proliferation, migration, adhesion and
the cell cycle (Figure 6).
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3. Discussion
We are the first group to establish that T1DM with good diabetic control and without cardiovascular
disease is associated with increased anti-angiogenic miRs; miR-21a, miR-222, miR-195. Furthermore,
we were able to validate that those miRs are associated with indices of vascular health or measures of
health improvement, including the effect of metformin therapy. Below we discuss individual findings
and what vascular effects of miRs studied by us are known in the literature.
3.1. miR-21a
1. Clinical Studies
We found plasma miR-21a expression to be significantly higher in T1DM in both the TG V1 and
SG V1 in comparison to the CG. Our data are concordant with another study, which demonstrated
high plasma and urine miR-21a lev l in T1DM versus controls [25]. Increased miR-21a levels in
T1DM are considered be an indicator of established or ongoing vascular damage [25]. An ongoing
inflammatory process demonstrating a direct correlation f C-reactive protein (CRP) with urinary
miR-21a is speculated to play a role in kidney damage [25]. Sala-Perez’s group has demonstrated
that iR-21a levels were reduced in peripheral blood mononuclear cells (PBMC) collected from
T1DM patients compared to healthy controls [28]. This might lead to a continued pro-i flammatory
environm nt, maintained by apo tosis-resistant PBMCs [28].
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It is of interest that plasma miR-21a levels in T2DM patients with a previous history of major
cardiovascular events (MACE) were significantly higher compared to other T2DM patients [29].
Furthermore, in the same study, miR-21a levels in circulating pro-angiogenic cells (CACs) were the
highest in T2DM patients with previous MACE compared to other T2DM patients. However, in
another group of T2DM patients, the opposite effect was observed: low plasma miR-21a levels were
recorded compared to controls [30]. Thus, the difference in miR-21a levels may be attributed to the
presence or absence of MACE events, which occurred in the former group, but not in the latter [30].
In a study of subclinical atherosclerosis, plasma miR-21a levels were positively correlated with
systolic, diastolic blood pressure, CRP and cIMT, but negatively correlated with nitric oxide (NO) and
eNOS [31]. Similarly, in acute coronary syndrome, miR-21 levels were increased and correlated with
CRP, age and visfatin, but negatively correlated with HDL-cholesterol [32].
3.1.2. miR-21a and Fibrosis
In T1DM animal models, hyperglycemia-induced miR-21a expression in mesangial cells led to a
reduction in phosphatase and tensin homolog (PTEN) expression, as well as a concomitant increase in
AKT serine/threonine kinase (Akt) phosphorylation [33]. In the same study, miR-21a-enhanced high
glucose-induced target of rapamycin complex 1 (TORC1) activity resulted in renal cell hypertrophy
and increased fibronectin expression [33].
miR-21a, which is highly expressed in diabetic skin, may have a functional role in wound healing
due to its effect on fibroblasts, which are involved in ulcer healing [34]. In contrast to the inhibitory
effect of miR-21a on endothelial cell migration, it has been demonstrated to promote fibroblast
migration, confirming a cell-specific effect for this miR [34]. Further evidence for a deleterious effect of
miR-21a comes from a study in which it promoted the progression of fibrosis upon ischemia-reperfusion
injury by regulating MMP-2 expression in the fibroblasts of the infarct zone by inhibition of PTEN, a
direct target of miR-21a [35].
3.1.3. miR-21a and Atherosclerosis
miR-21a has been shown to be involved in the pathogenesis of proliferative vascular disease
such as atherosclerosis as it is upregulated in atherosclerotic plaques [36]. A study of additional
pathway regulation confirmed miR-21a as a new angiogenesis inhibitor as it reduced cell migration and
tubulogenesis through repression of RhoB [37]. Overexpression of miR-21a promotes inflammation
by directly targeting and downregulating peroxisome proliferator-activated RT-qPCR receptor-α
(PPAR-α), which increases the adhesion of monocytes to endothelial cells (ECs) and results in the
increased pro-inflammatory responses of vascular endothelial cells [38].
In vivo and in vitro data have also suggested that hypoxia-induced miR-21a expression in
EPCs leads to growth arrest and that an inhibitory effect of miR-21 on EPCs proliferation and
angiogenesis is mediated by activating the transforming growth factor-beta (TGF-β) signaling
pathway via downregulation of the WW domain-containing protein 1 (WWP1) [39]. In contrast,
inhibition of miR-21a improved the migratory function of circulating angiogenic progenitor cells
(APCs) [40], and its suppression improved EPCs’ survival by increasing high-mobility group A2
protein (HMGA2) [41]. The above-mentioned data thus confirm an inhibitory effect of miR-21a on
angiogenesis and vascular repair.
3.1.4. miR-21a and Vascular Smooth Muscle Cells
It is clear that miR-21a is tissue specific as its proliferative effect has been observed in VSMC, the
developmental model of atherosclerosis. Upregulation of miR-21a in VSMCs has been shown to inhibit
PTEN, thereby inhibiting apoptosis and promoting VSMC proliferation [42].
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3.1.5. The Effect of miR-21a on Other Cell Types
In the central nervous system, increased expression of miR-21a suppresses pro-apoptosis genes,
Fas ligand (FasL), PTEN and programmed cell death protein 4 (PDCD4) in vitro, which are direct
targets of it [43]; whilst in vivo treatment with antagomir-21 increases the expression of FasL and
PTEN but has no effect on PDCD4. These results suggest that miR-21a plays an important role in
limiting secondary cell death following spinal cord injury and that its protective effects might be
related to its regulation of pro-apoptotic genes [43]. Therefore, miR-21a expression in different cells
with their own unique function/genetic component is likely to play a role in the development of
vascular disease. We believe that high plasma miR-21a levels in our T1DM cohort confirm an ongoing
process of diabetes-related vascular pathogenesis and its clinical complications.
In our MERIT Study, we have shown for the first time that metformin decreases miR-21a plasma
levels in T1DM patients independent of improving glycemic control, whilst a standard treatment group
(SG) without metformin over eight weeks’ follow-up did not show any change in plasma miR-21a
levels. In a high-fat dietary rat model, metformin ameliorates skeletal muscle insulin resistance by
inhibiting miR-21a expression in a dose-dependent manner [44]. In this model, miR-21a expression
correlates directly with homeostatic model assessment-insulin resistance (HOMA-IR, index of insulin
resistance) and inversely with insulin sensitivity (HOMA-ISI) [44].
The indirect evidence of metformin’s effect on miR-21a downregulation has come from
suppression of the TGF-β pathway in cardiac fibroblasts [45]. In ECs, metformin has been demonstrated
to inhibit the nuclear factor-κB signaling pathway and activate AMPK-induced PTEN expression,
leading to decreased inflammatory response in VSMCs [46].
The flow diagram in Supplementary Figure S1 provides a summary of miR-21a action in the
development of vascular disease in T1DM (Supplementary Figure S1a) and the protective effect of
metformin (Supplementary Figure S1b) based on the evidence discussed above.
3.2. miR-222
Clinical Studies
miR-222 and miR-221 are located on the same gene, separated by a distance of 726 base pairs.
They both play a vital role in vascular homeostasis. Most studies have evaluated mir-221 and miR-222
concurrently. However, in our study, the miR-221 Cq (quantification cycle) value was high (>35.00).
This indicates that plasma levels of this miRNA are very low and cannot be reliably measured in
plasma. It also has a high coefficient of variation (CV%). Therefore, we have only evaluated miR-222.
We have demonstrated that plasma levels of miR-222 are significantly higher in T1DM individuals
(TG V1) compared to the CG and are similar to those in SG V1. However, although miR-222 levels
were higher in SG V1 compared to CG, this was not statistically significant, probably due to a smaller
number of subjects in the SG. Overall, our miR-222 results are concordant with other research, which
has demonstrated that miR-222 levels are elevated in T2DM [26]. Individuals with hypertension,
metabolic syndrome, insulin resistance and CVD may also have raised plasma miR-222 levels [47].
Our work is the first study to show that miR-222 is negatively correlated with in vivo endothelial
function (RHI), thus validating its anti-angiogenic properties in clinical practice consistent with its
negative effect on the endothelium.
As the miR-222 cluster is highly expressed in quiescent ECs, this suggests that miRNA has a
critical role in regulating the development and function of the vascular endothelium. However, it is
important to remember that the role of miR-221/222 in vascular ECs greatly varies depending on the
subject’s developmental stage and microenvironment.
In an inflammatory microenvironment, miR-222 has been demonstrated to be the main regulator
of vascular homeostasis by negatively regulating the signal transducer and activator of transcription
5A (STAT5A) [48]. STAT5A is a transcription factor that regulates the expression of genes involved
in cell proliferation, survival and differentiation [49]. The other mechanism of action of miR-222 is
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via reduction of eNOS protein in ECs [50]. Both miR-222 and miR-221 are highly expressed in human
aortic ECs undergoing senescence. miR-222 negatively affects eNOS activity and synthesis in these
cells [51].
Other anti-angiogenic mechanisms demonstrated by the miR-222 cluster were reported by
Poliseno et al. They observed that miR-222 attenuated the angiogenic function of the stem cell
factor by affecting the expression of c-kit [52]. This anti-angiogenic effect appears to be cell specific,
as its overexpression in ECs reduces angiogenesis, whilst in cancer, cells increased angiogenesis [53].
Further evidence for a cell-specific action of miR-222 is derived from experiments using VSMCs.
miR-222 stimulated proliferation, migration and attenuated apoptosis of VSMCs, thus displaying
pro-atherogenic properties [54]. The opposing cellular effect of miR-221/222 on proliferation, migration
and apoptosis of ECs and VSMCs allows miR-221/222 to promote neointimal formation while
inhibiting re-endothelialization after vascular injury [54]. Vascular expression of miR-221/222 was
upregulated in initial atherogenic stages, causing inhibition of angiogenic recruitment of ECs and
increasing endothelial dysfunction and EC apoptosis. These miRNAs stimulated VSMCs and switched
from the VSMC “contractile” phenotype to the “synthetic” phenotype associated with the induction of
proliferation and motility [54].
Further tissue-specific effects of miR-222 are related to the expression profiles of its target genes [54].
At the site of vascular injury, platelets and ECs release platelet-derived growth factor (PDGF), which
induces expression of miR-222 and miR-221 [55]. Increased expression of miR-222/miR-221 reduces levels
of p27kip1 [54], which is known to attenuate atherosclerosis development, whilst reduced expression of
p27kip1 in aortic tissue led to the development of atherosclerotic plaque [56].
Another important finding in our study was the positive correlation between miR-222 levels and
CD34+ progenitor cells, but not with differentiated cEPCs (CD45dim CD34+ VEGFR2+). As there was no
correlation between miR-222 and CD34+ in CG, we can infer that a diabetic environment contributed
to the association between plasma miR-222 levels and undifferentiated CD34+ cells. Our observation is
supported by research from others where miR-222 has been found to be highly expressed in CD34+
hematopoietic cells from both umbilical cord blood and bone marrow [53]. Furthermore, miR-222
reduced the differentiation of hematopoietic progenitor cells [57]. It has been suggested that this
mechanism is mediated through the c-kit and/or eNOS pathways [50,58].
All the above evidence indicates miR-222 to be a key player in vascular biology through its
contribution to vascular remodeling, an adaptive process involving phenotypic and behavioral changes
in vascular cells in response to vascular injury. One can conclude that the miR-222 cluster is primarily
responsible for maintaining endothelial integrity and supporting the quiescent EC phenotype. Vascular
expression of miR-221/222 is upregulated in the initial atherogenic stages causing the inhibition of
angiogenic recruitment of ECs and increasing EC dysfunction and apoptosis, whilst in proliferative
vascular diseases such as atherosclerosis, pathological vascular remodeling plays a prominent role.
In atherosclerotic vessels, miR-221/222 drive neointimal formation. Both miRNAs contribute to
the atherogenic calcification of VSMCs. In advanced plaques, chronic inflammation downregulates
miR-221/222 expression in ECs, which in turn may activate intralesional neo-angiogenesis [47].
Thus, it appears that miR-222 is involved in both physiological and atherosclerotic vascular remodeling.
To our knowledge, we are the first group to show that eight weeks of metformin treatment reduces
plasma miR-222 levels in patients with T1DM. Furthermore, miR-222 levels were reduced to levels
similar to those in healthy controls.
Our findings are concordant with two previously published studies in T2DM, which showed
that metformin treatment, whilst lowering blood glucose concentration, reduces plasma miR-222
levels and miR-222 expression in the internal mammary artery [26,59]. In the former study, miR-222
reduction coincided not only with improved diabetic control, but also correlated with improved
insulin sensitivity during the insulin clamp. In keeping with this relationship, the same group has
shown that miR-222 levels increased following infusion of an intralipid-heparin mixture suggesting
that miR-222 is related to insulin resistance [26]. Therefore, decreased miR-222 expression in the
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diabetic microenvironment may enhance the angiogenic pathway and vascular repair. In our study,
we aimed to keep diabetic control unchanged, in order to remove the possibility of metabolic
improvement as the mechanism behind metformin action on miR reduction. Thus, we can conclude
that metformin has cardioprotective effects beyond its effect on glucose levels. Another example
of cardioprotection by reducing miR-222 levels comes from using cholesterol-lowering agents.
In patients with coronary artery disease, treatment with the drug, atorvastatin (a well-documented
cardioprotective, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor) reduces
miR-222 expression in EPCs, leading to their increased mobilization via the eNOS-dependent pathway,
confirming the mechanism suggested by our study [58].
To further confirm our conclusion, we have shown an additional positive correlation between the
reduction in plasma miR-222 levels and a reduction in circulating EC levels, a marker of endothelial
injury, supporting evidence for metformin’s cardioprotective effects on miR-222 and endothelial
homeostasis beyond improving diabetic control.
Thus, we can infer that metformin decreases vascular damage by improving miR-222 levels.
Further work using miR-222 knock-in and knock-down in a culture microenvironment should
be conducted to evaluate downstream pathways. The flow diagram in Supplementary Figure S2
summarizes miR-222 action in the development of vascular disease in T1DM (Supplementary
Figure S2a) and the protective effect of metformin (Supplementary Figure S2b) based on the evidence
discussed above.
3.3. miR-195
To our knowledge, we are the first group to show that plasma levels of miR-195 are significantly
higher in T1DM patients in the TG V1 and SG V1 compared to the CG. When the TG V1 and SG V1
groups were compared, miR-195 levels were significantly higher in the TG probably due to the smaller
number of subjects in the SG.
As miR-195 has been shown to be elevated in patients with acute myocardial ischemia, it has been
defined as a biomarker of CVD [60]. In contrast to our data, miR-195 levels have also been observed to
be significantly lower in T2DM [26]. The difference in the results might be multifactorial, including
studying T2DM rather than T1DM [26].
In the animal model of T1DM, miR-195 has been linked to diabetes-related complications [61].
It has been demonstrated that miR-195 plays a major role in diabetic retinopathy by downregulating
sirtuin 1 (SIRT1) and anti-apoptotic protein [61]. In the animal model of both T1DM (streptozotocin)
and T2DM (db/db mouse), increased miR-195 reduced SIRT-1 levels in mouse hearts, whilst knocking
down miR-195 expression, decreasing oxidative stress, increasing myocardial capillary density and
improving maximal coronary blood flow [62].
In experimental gerontology, abrogation of age-induced miR-195-rejuvenated senescent
mesenchymal stem cells (MSCs) has been achieved by reactivating telomerase [63]. This was achieved
by silencing miR-195 in old MSCs by transfection of a miR-195 inhibitor and significantly restoring
anti-aging factor expression including telomerase reverse transcriptase (Tert) and Sirt1, as well as
phosphorylation of Akt and forkhead box protein O1 (FOXO1). Furthermore, transplantation of
old MSCs with knocked-out miR-195 reduced myocardial infarct size and improved left ventricular
function, due to increased MSC proliferative capabilities [63].
miR-195 and Metabolism
The additional metabolic effects of increased miR-195 levels have been studied in hepatocytes [64].
Overexpression of miR-195 by saturated fatty acids or a high fat diet impaired the insulin signaling
cascade and glycogen synthesis in HepG2 cells. Furthermore, miR-195 directly suppresses the
expression of insulin receptor (INSR), by targeting the INSR-3’UTR [64]. Thus, based on the evidence
mentioned above, we can infer that high miR-195 levels in T1DM can be linked to the development of
diabetes-related complications and CVD.
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To our knowledge, we are the first group to demonstrate that eight weeks of metformin therapy
significantly reduces miR-195 levels in T1DM patients. In tissue cultures, metformin has been shown to
attenuate hyperglycemia-related endothelial senescence due to partly restoring SIRT-1 expression [65].
Moreover, restoring SIRT1 expression has been demonstrated to play a protective role in diabetes
vasculopathy [66]. Thus, based on the above-discussed evidence, we hypothesize that metformin’s
effect in reducing miR-195 expression may lead to a decreased risk of developing diabetes-related
complications, by improving SIRT-1 expression. In our study, diabetic control was kept purposefully
unchanged, so metformin displayed properties beyond improving glycemia. As it is well established
that hyperglycemia itself decreases SIRT1 expression, metformin may act in two ways, via miR-195
reduction and by improving glycemic control (thus also indirectly improving SIRT-1). Therefore, it
may be an adjunct cardioprotective therapy with dual action. Supplementary Figure S3a describes
the schematic relationship between miR-195 and factors involved in angiogenesis and Figure S3b the
effect of metformin on the interactions described in the evidence discussed above.
3.4. miR-126
Our results showing that metformin treatment did not change plasma miR-126 levels are not
surprising. This is in line with data from a T2DM study in which three months of metformin treatment
did not alter the expression of miR-126 plasma levels [26]. Therefore, we can conclude that metformin
is unlikely to affect plasma miR-126 levels.
3.5. MicroRNA Pathway Identification (DIANA Tools miRPath)
We explored which pathways may be affected by the three significantly reduced (miR-21a,
miR-222 and miR-195) anti-angiogenic miRs using DIANA Tools miRPath (Figure 5) [27]. Pathway
analysis demonstrated that in T1DM angiogenesis, cell proliferation, migration, adhesion, cell cycle and
apoptosis pathways are all likely to be dysregulated in T1DM. To support our findings that metformin
directly or indirectly affects miR levels, it has been established that metformin treatment increases
levels of the microRNA-processing protein DICER1 in patients with DM by upregulating it through
a post-transcriptional mechanism involving the RNA-binding protein AUF1. Metformin treatment
decreases cellular senescence in several senescence models in a DICER1-dependent manner [67].
Additionally, our previous study on HUVEC induced by hyperglycemia-hypoxia proved that
metformin significantly enhances cell migration and inhibits apoptosis [13].
Thus, our data have yielded important information regarding angiogenic signals generated by
metformin cardioprotective therapy. Our work can be meaningfully extended by exploring miR targets
and downstream protein expression for the design of future therapeutic agents. The gain and loss of
miR function in vitro and in vivo experiments will yield information regarding individual miRs and
their functions. This will be important in not only exploring the function of circulatory biomarkers,
but also in identifying prognostic markers and future treatment targets.
In summary, well-controlled T1DM is associated with increased circulating levels of the
anti-angiogenic miRs; miR-21a, miR-222 and miR-195, confirming an increased cardiovascular risk in
this disease group. miR-222 expression correlates with endothelial dysfunction, vascular injury and
CD34+ cell levels. The cardioprotective effect of metformin may be mediated by downregulation of
these three anti-angiogenic miRs.
4. Materials and Methods
4.1. MERIT Study
Plasma samples were used for miRs analysis from our patients and healthy controls who
participated in the MERIT Study. Blood samples were collected at baseline (i.e., pre-treatment or
pre-observation period) and at the end of the study.
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The clinical study has been discussed previously [14]. In summary, 23 patients, aged 40.6 ±
4 years old with T1DM (HbA1c 7.3% or 56.4 mmol/mol) were recruited, as TG was treated with
metformin. We included 9, age (47 ± 14 years), sex matched T1DM patients as SG (Table 1). The
study protocol consisted of two phases: a run-in phase of 6 weeks ensured stable glucose control,
which was followed by a treatment/observation phase. Metformin was given for 8 weeks to TG with
a dose titrated up to a maximum of 1 g twice a day over 2–3 weeks or to the highest tolerated dose.
The SG underwent similar follow-up except for metformin treatment. The dose of insulin was adjusted
during the study to maintain unchanged the control confirmed by HbA1c and continuous glucose
monitoring [14]. Furthermore, the TG was compared with 23 age 39.7 ± 10.3 year and gender-matched
non-diabetic HC.
The clinical trial was approved by the NHS Health Research Authority, NRES Committee North
East-Sunderland, UK (Research Ethics Committee Reference Number 12/NE/0044) on 29th of March
2012 and all subjects had given informed written consent. The study was performed in compliance
with the Helsinki Declaration.
4.2. Vascular Function Measurements by Peripheral Tonometry (Endo-PATTM)
An EndoPATTM 2000 (Itamar Medical Ltd., Keisarya, Israel) device was used to assess endothelial
function (flow-mediated dilatation). This was measured before metformin therapy and at the end of
the study. EndoPAT measurements were taken in the active intervention group only in the morning
after overnight fasting as per Itamar recommendation. The data were analyzed by the EndoPAT
software and presented as RHI, that is post-occlusion to pre-occlusion ratio. An RHI value of 1.67 or
above was considered as normal [68].
4.3. Endothelial Progenitor Cells
Peripheral blood samples were collected in EDTA tubes before and after the intervention phase
for the TG and SG and at baseline for the CG. The first 4 mL of collected blood were not used for cEPC
analysis to avoid spurious results. Blood samples were processed within 4 h of collection.
4.4. Flow Cytometric Evaluation of Circulatory Endothelial Progenitor Cells and of Circulatory
Endothelial Cells
Whole blood (100 µL) was incubated with 5 µL of V500 CD45 (BD Bioscience, San Jose, CA, USA),
20 µL of PerCP-Cy5.5 CD34 (BD Bioscience, San Jose, CA, USA), 5 µL of PE VEGFR-2 (R & D Systems,
Minneapolis, MN, USA ), 5 µL APC CD133 (Miltenyi Biotic Inc., Bergisch Gladbach, Germany) and
10 µL of FITC CD144 (BD Bioscience, San Jose, CA, USA) for 30 min. Subsequently, 2 mL of PharmLyse
(BD Bioscience, San Jose, CA, USA) were used to lyse the red cells. The sample was then analyzed by
flow cytometry on a BD FACS Canto™ II system and the results data processed using BD FACSDiva™
software as described previously [14].
4.5. Plasma Collection for miR Studies
Platelet-free plasma (PFP) was extracted from peripheral blood, collected in EDTA vacutainer
tubes from subjects after an overnight fast. Samples were centrifuged for 15 min at 500× g. The upper,
clear fraction (platelet-rich plasma, PRP) was collected without disturbing the bottom cellular layer
and transferred to 1.5-mL polypropylene tubes. These PRP samples were further centrifuged for 5 min
at 13,000× g in a microcentrifuge. After centrifugation, the clarified PFP was collected and stored at
−80 ◦C for subsequent analysis.
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4.6. miR Level Assay Using Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction
miR levels were assayed directly from PFP using the TaqManTM RT-qPCR platform (Life
Technologies, Paisley, UK) following the Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines [69]. Control samples (RT control) for each miR
were prepared in parallel for each patient, and the reverse transcriptase enzyme was omitted from
the reaction mix to avoid false-positive results due to DNA contamination. The PFP were diluted 1:3
with nuclease-free water (Ambion, Paisley, UK). The diluted PFP were heated to 95 ◦C for 10 min then
cooled to 4 ◦C. The TaqManTM MicroRNA Reverse Transcription Kit (Life Technologies, Paisley, UK)
was used to prepare the reverse transcription reactions according to the manufacturer’s instructions.
Two-microliter aliquots of the reverse transcription reaction product were combined with 18 µL
of PCR master mix (10 µL 2× TaqMan Fast Advanced master mix (Life Technologies, Paisley, UK),
1 µL 20× miRNA assay (Life Technologies, Paisley, UK), 7 µL nuclease-free water). The amplification
reactions were performed using the Applied Biosystems 7900HT Fast Real-Time PCR system (Life
Technologies, Paisley, UK) as follows: 50 ◦C for 2 min, 95 ◦C for 20 s followed by 50 cycles of 95 ◦C for
1 s and 60 ◦C for 20 s. The samples were tested in triplicate.
The Cy0 method was used to quantify the expression of miRNA using the PCR kinetics equation
described by others, R0 = RCq x 2−Cq [70], where R0 and RCq are initial fluorescence and fluorescence
at Cq (quantification cycle) values, respectively. The advantage of the Cy0 method is to minimize
the variation introduced due to slight inhibition. This inhibition may be caused by the carry-over of
reagents during the RNA extraction. Such inhibition leads to the shifting of the amplification curve to
the right, generating higher Cq values than those found under optimal amplification conditions and
thus underestimating the target amount.
4.7. Statistical Analysis
The results are presented as the mean ± SEM unless stated otherwise. Log transformation of
miR expression was carried out before performing the comparisons and correlations. The unpaired
Student t-test or the Mann–Whitney test was used for the comparison between the groups. The paired
Student t-test or Wilcoxon signed rank test was used within the intervention/observation group
depending on the type of data distribution. Statistical significance was accepted at p < 0.05 (two-tailed
significance). All analyses were conducted using IBMTM SPSSTM software Version 23 (SPSSTM Inc.,
Armonk, NY, USA).
5. Conclusions
Metformin, with its proven life-extending interventions, can be considered as a pro-angiogenic
and rejuvenating agent by affecting the differential patterns of miR expression.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/10/
3242/s1.
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Abbreviations
Akt AKT serine/threonine kinase
APC Angiogenic progenitor cell
BMI Body mass index
CAC Circulating pro-angiogenic cell
cEC Circulating endothelial cell
cEPC Circulating endothelial progenitor cell
CG Healthy control group
CHD Coronary heart disease
cIMT Carotid intima media thickness
CPR C reactive protein
Cq Quantification cycle
CVD Cardiovascular disease
EC Endothelial cell
eNOS Endothelial NO synthase
FasL Fas ligand
FOXO1 Forkhead box protein O1
HMGA2 High-mobility group A2
HOMA Homeostatic model assessment
INSR Insulin receptor
MACE Major cardiovascular events
MI Myocardial infarction
miR MicroRNA
MMP Matrix metalloproteinase
mRNA Messenger RNA
MSC Mesenchymal stem cell
NO Nitric oxide
PBMC Peripheral blood mononuclear cells
PCI Percutaneous coronary intervention
PDCD4 Programmed cell death protein 4
PDGF Platelet derived growth factor
PFP Platelet free plasma
PPAR-α Peroxisome proliferators activated receptor-α
PRP Platelet rich plasma
PTEN Phosphatase and tensin homolog
RHI Reactive hyperemia index
RT-qPCR Reverse transcription quantitative real-time polymerase chain reaction
SG Standard group
SIRT1 Sirtuin 1
STAT5A Signal transducer and activator of transcription 5A
T1DM Type 1 diabetes
Tert Telomerase reverse transcriptase
TG Treatment group
TGF-β Transforming growth factor-beta
TORC1 Target of rapamycin complex 1
VEGF Vascular endothelial growth factor
VSMC Vascular smooth muscle cell
WWP1 WW domain-containing protein 1
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